H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026

H.C. Wainwright maintained a Buy rating on Fulcrum Therapeutics, Inc. (FULC) on February 24, 2026 after reviewing PIONEER data for pociredir. This FULC analyst rating reflects a continued bullish stance rather than a fresh upgrade or downgrade. The firm emphasized the drug’s differentiated profile while not publishing a new price target. The market reaction showed a short-term pullback of -6.92% ($-0.64), and FULC’s market cap stands at $464,275,623. Meyka AI rates FULC with a grade of B+, combining benchmark and consensus metrics into a single view